Navigation Links
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator
Date:11/13/2009

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator. Kim Eldridge, Registered Nurse, with over 10 years of clinical experience in complex wound care, is a pioneer in the field of wound care; and is dedicated to providing the highest standards of care, improving clinical outcomes, emphasizing patient education, and ensuring healthcare accessibility and cost-efficiency.

(PRWEB) November 13, 2009 --

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator.

Kim Eldridge, Registered Nurse, was born and raised in Meridian, Mississippi, and has over 10 years of clinical experience in complex wound care. Her commitment to provide the highest standards of wound care, while improving clinical outcomes and emphasizing patient education, and her passion for ensuring healthcare accessibility and cost-efficiency, make Kim a pioneer in the field of wound care.

Kim has been a surgical nurse for over 17 years. She works exclusively with a general surgeon who specializes in wound care, hyperbaric therapy, and limb salvage. She provides surgical wound care in both acute and long term settings, and also consults for major wound care companies and organizations nationwide. She has published several posters and articles in the field of wound care education. Kim is a Registered Nurse First Assistant, and is a certified surgical, foot care and wound care nurse.

Maggie Jankowski, COO of Wake Pharma US, Inc. commented, “Kim Eldridge has been an invaluable resource to the Wound Be Gone® brand. Her clinical insight and experience has been a tremendous asset to our development team. We believe that Kim Eldridge, RN, will help us accelerate the growth
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator 
(Date:5/30/2015)... 2015 On Sunday, June 14, 2015, ... – Jefferson Health will host Journey to Survivorship, a ... speaker, brunch and resources for cancer survivors and their ... the event will be Kathy LaTour, editor-at-large for Cure ... then again in 2007, LaTour provides a unique perspective ...
(Date:5/30/2015)... Chicago, Il (PRWEB) May 30, 2015 ... for Clinical Oncology (ASCO) Annual Meeting 2015 show activity ... cancer, in one case specifically against brain metastases and ... HER2+ breast cancer patients. , "I am thrilled to ... patient in her early 40s. She didn't have any ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
(Date:5/30/2015)... 2015 San Luis Obispo insurance ... offering a free analysis and consultation for anyone interested ... Disability Awareness Month, which was created by the non-profit ... United States such as Polk recognize the proclamation, and ... the possibility of disability, as well as the often-overlooked ...
Breaking Medicine News(10 mins):Health News:Abington Hospital to Host Cancer Survivorship Event 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... efforts,to mobilize opposition to the Bush Administration,s planned $770 ... benefits in the,year ahead, the Coalition to Protect Senior ... to go on record publicly opposing,cuts to seniors, Medicare ... an especially negative impact on rural America,s nursing home,care., ...
... KALAMAZOO, Mich., May 28 Stryker Corporation,(NYSE: SYK ... following,investor conferences:, June 11, 2008 - 9:00 ... LLC Biotechnology and Medical Technology Conference New ... a.m. Pacific Time Goldman Sachs Twenty-Ninth Annual Global ...
... experts don,t endorse use of the drugs to combat ... painkillers called non-steroidal anti-inflammatory drugs (NSAIDs) appear to reduce ... medication in the class works better than the others, ... the largest of its kind, contradicts some previous studies ...
... -- WASHINGTON, DC) The American College of ... announced today a multi-year partnership to jointly sponsor ... Fla., March 2831, 2009, during ACC.09, the ACCs ... cardiovascular meeting. This will be the beginning ...
... FDA,s Janet Woodcock, MD, Provides,Practical Guidance on New ... that the Food and,Drug Administration (FDA) has new ... manufacturers can be required to develop,comprehensive risk assessment ... To help pharmaceutical companies, consultants and other drug ...
... Health Care Association: Rising Energy and Food Costs, Existing,Medicaid ... Texas, May 28 A new national study,analyzing how ... rural America,s seniors and nursing homes finds Texas will ... Texas Health Care,Association (THCA) to warn that yet another ...
Cached Medicine News:Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 2Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 3Health News:Stryker to Present at Investor Conferences 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 3Health News:ACC and CRF announce partnership on ACC's Innovation in Intervention: i2 Summit 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 3
(Date:5/29/2015)... May 28, 2015 Research and Markets ( ... "North America Open System MRI Market - Growth, Trends ... offering. The key players in the industry ... Siemens Healthcare and Toshiba Medical Systems ... replacing CT because of its higher sensitivity and use ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cardiovascular ... to their offering. Drug delivery to ... other systems because of the anatomy and physiology ... nutrients to all organs of the body. Drugs ...
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
Breaking Medicine Technology:North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3LifeNet Health to add more than 160 jobs in 2015 2
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... today that it has commenced vaccination of,volunteers for ... pandemic,influenza H5N1 vaccine. The Phase II clinical trial ... and efficacy of the pandemic,influenza H5N1 vaccine. The ...
... 11 ImClone Systems,Incorporated (Nasdaq: IMCL ... BMY ),today announced that a Phase III ... chemotherapy (vinorelbine plus cisplatin),met its primary endpoint ... in patients with advanced non-small cell lung ...
Cached Medicine Technology:Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 3ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 4ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 5ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 6ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 7ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 8ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 9
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Multi-curved shafts with straight blades and longitudinal serrations. Slide lock and serrated handle with polished finish. Blade length: 27 mm....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. Straight shafts. Cross action. Round handle....
Medicine Products: